Spero Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information

Select the Comparisons :

Growth Rates ▼

Select the Ratio:

None▼

Growth Rates ▼

None▼

Download as CSV

SPRO Revenue Growth Rate Comparisons	Company	Industry	Sector	S&P 500
Y / Y Revenue Growth (Q3 MRQ)	-59.6 %	10.1 %	7.64 %	7.96 %
Q / Q Revenue Growth (Q3 MRQ)	-61.65 %	6.05 %	4.36 %	4.62 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM)	-61.91 %	9.32 %	7.79 %	%
Sequential Revenue Growth (for 12 months ending Q3 TTM)	-16.52 %	2.33 %	2.18 %	1.99 %
Revenue 5 Year Average Growth	21.46 %	9.02 %	8.22 %	7.56 %

SPRO's Growth Comparisons in III. Quarter 2025

As Spero Therapeutics Inc 's sales faded by -59.6% year on year in the third quarter 2025, the Major Pharmaceutical Preparations industry grew by 10.1%, Spero Therapeutics Inc 's third quarter 2025 performance was trailing the Major Pharmaceutical Preparations industry in the third quarter 2025, and underperformed the 7.64% Revenue growth in the Healthcare sector. Comparing the third quarter, sales Spero Therapeutics Inc was trailing overall market not just Major Pharmaceutical Preparations industry.

Top-line fell by -61.65% from the second quarter results. Comparing the annual growth, sales of 21.46% on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2025 financial results, average yearly sales growth is 7.56%. Spero Therapeutics Inc grew faster than the market.

SPRO Growth Rates by Company's Segments

Segment Name	Y / Y	Sequential
Grant Revenue	-57.63 %	0.29 %
Collaboration revenue - related party	-60.69 %	-74.17 %
Total	-59.6 %	-61.65 %

Growth Rates of SPRO's Income in the third quarter 2025

SPRO Operating Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Operating Income Change (Q3 MRQ)	-	34.93 %	28.02 %	15.18 %
Sequential Operating Income Change (Q3 MRQ)	-	12.52 %	10.35 %	7.5 %
Y / Y Operating Income Growth (Q3 TTM)	-	93.58 %	56.5 %	6.78 %
Sequential Operating Income Growth (Q3 TTM)	-	9.05 %	6.52 %	3.69 %
Operating Income 5 Year Avg. Change	-	-1.79 %	-1.82 %	9.14 %

Income from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ)	-	54.05 %	30.77 %	19.52 %
Sequential Income from Cont. Ops. Change (Q3 MRQ)	-	14.96 %	14.73 %	2.98 %
Y / Y Income from Cont. Ops. Change (Q3 TTM)	-	143.99 %	101.35 %	14.87 %
Sequential Income from Cont. Ops. Change (Q3 TTM)	-	12.81 %	7.66 %	4.59 %
Income from Cont. Ops. 5 Year Avg. Change	-	-3.66 %	-9.06 %	9.13 %

SPRO Net Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Net Income Growth (Q3 MRQ)	-	55.7 %	20.24 %	18.78 %
Q / Q Net Income Growth (Q3 MRQ)	-	15.14 %	15.68 %	3.06 %
Y / Y Net Income Change (Q3 TTM)	-	144.98 %	88.7 %	15.72 %
Sequential Net Income Change (Q3 TTM)	-	12.79 %	4.81 %	4.42 %
Net Income 5 Year Avg. Growth	-	-4.66 %	-8.54 %	8.69 %

SPRO's EPS Growth Rates

EPS from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ)	-	51.25 %	30.77 %	19.52 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ)	-	13.01 %	14.73 %	2.98 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM)	-	-	-	-
Sequential EPS from Cont. Ops. Change (Q3 TTM)	-	-	-	-47.95 %
EPS from Cont. Ops. 5 Year Avg. Growth	-	-11.79 %	-9.06 %	9.13 %

SPRO EPS Net Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS Net Growth (Q3 MRQ)	-	52.87 %	20.24 %	9.13 %
Q / Q EPS Net Growth (Q3 MRQ)	-	13.18 %	15.68 %	3.06 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM)	-	-	-	-66.91 %
Sequential EPS Net Change (for 12 months ending Q3 TTM)	-	-	-	-47.94 %
EPS Net 5 Year Avg. Change	-	-4.66 %	-8.54 %	8.69 %

Spero Therapeutics Inc reported bottom-line of $ -0.13 in the third quarter, compare to $ -0.32 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 52.87%, while Healthcare sector increased by 20.24%, and overall market improved by 18.78%.

Bottom-line fell by -61.65% from the second quarter results. Comparing the annual growth, income per share of 21.46% on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2025 earnings, average yearly income per share growth is 8.69%. Spero Therapeutics Inc grew faster than the market.

SPRO Cash Flow Growth Rates

Free Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ)	36.5 %	13.13 %	21.57 %	76.78 %
Sequential Free Cash Flow Change (Q3 MRQ)	-	120.43 %	100.38 %	27.6 %
Y / Y Free Cash Flow Change (Q3 TTM)	-	20.81 %	17.93 %	19.84 %
Sequential Free Cash Flow Change (Q3 TTM)	-	5.57 %	6.97 %	13.42 %
Free Cash Flow 5 Year Avg. Change	-	9 %	4.78 %	8.26 %

Net Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ)	36.5 %	-	-	-
Sequential Net Cash Flow Change (Q3 MRQ)	-	-	-	-
Y / Y Net Cash Flow Change (Q3 TTM)	-	-	527.52 %	-
Sequential Net Cash Flow Change (Q3 TTM)	-	-	-	-
Net Cash Flow 5 Year Avg. Change	-	-31.22 %	-19.37 %	0.42 %

Capital Expenditures	Company	Industry	Sector	S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ)	-	19.01 %	10.82 %	22.55 %
Sequential Capital Expenditures Change (Q3 MRQ)	-	15.26 %	12.67 %	8.68 %
Y / Y Capital Expenditures Change (Q3 TTM)	-	17.2 %	7.36 %	23.2 %
Sequential Capital Expenditures Change (Q3 TTM)	-	6.43 %	3.1 %	5.37 %
Capital Expenditures 5 Year Avg. Change	-	9.47 %	8.03 %	7.58 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

Dividend Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.